文献速递产科

预防性宫缩剂联合用药在产程停滞剖宫产中减少额外宫缩剂需求的随机对照试验

Prophylactic Administration of Uterotonics to Prevent Postpartum Hemorrhage in Women Undergoing Cesarean Delivery for Arrest of Labor: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2021-01-01

该双盲三臂随机对照试验纳入105名因产程停滞行剖宫产的产妇,比较缩宫素单用与缩宫素联合麦角新碱或卡前列素氨丁三醇预防性给药的效果。

要点

  • 缩宫素联合麦角新碱或卡前列素氨丁三醇未减少术中额外宫缩剂需求。
  • 三组额外宫缩剂使用率分别为37%、33%、34%,无统计学差异。
  • 麦角新碱组恶心呕吐发生率85%,显著高于缩宫素组的51%。

核心结论

  • 与单用缩宫素相比,预防性联合使用宫缩剂并未减少因产程停滞行剖宫产时额外宫缩剂的需求。

研究设计与样本

  • 双盲、三臂随机对照试验,2013年6月至2019年7月共随机105名因产程停滞行剖宫产的产妇,每组35人,最终分析100人(缩宫素组35人、缩宫素+麦角新碱组33人、缩宫素+卡前列素氨丁三醇组32人)。

主要发现

  • 子宫张力和计算失血量在三组间相似。

关键数值与推荐

  • 缩宫素组:缩宫素5单位静脉单用;联合组:缩宫素5单位静脉联合麦角新碱0.25 mg静脉或卡前列素氨丁三醇0.25 mg肌内注射,产后立即给药,随后所有组维持缩宫素输注40毫单位/分钟。

临床怎么用

  • 对于因产程停滞行剖宫产的产妇,预防性联合使用麦角新碱或卡前列素氨丁三醇并未比单用缩宫素更有效地减少额外宫缩剂需求。
  • 联合用药时需注意麦角新碱可能增加恶心呕吐风险。

局限性

  • 样本量较小,每组约33-35例,可能影响对次要结局的统计效能。
  • 研究仅纳入因产程停滞行剖宫产的产妇,结论不能推广至其他剖宫产人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether prophylactic administration of oxytocin plus ergonovine or oxytocin plus carboprost is more effective than oxytocin alone in reducing the need for additional uterotonics among women undergoing cesarean delivery for labor arrest. METHODS: In this double-blind, three-arm randomized controlled trial, participants were assigned to receive either oxytocin 5 units intravenous alone, or with ergonovine 0.25 mg intravenous or carboprost 0.25 mg intramuscular immediately after delivery, followed with maintenance infusion of oxytocin 40 milliunits/minute in all groups. Uterine tone was assessed at 3, 5, and 10 minutes after delivery, and additional uterotonics were administered if deemed necessary. The primary outcome was intraoperative need for additional uterotonics. Secondary outcomes included uterine tone, calculated blood loss, and side effects. A sample size of 34 per group (n=102), based on the null hypothesis that there is no association between treatment assignment and the need for additional uterotonics, permitted independent post hoc pairwise comparisons between oxytocin plus ergonovine, oxytocin plus carboprost, and oxytocin alone using an adjusted P-value of .025. The association between the need for additional uterotonics and treatment group was assessed using the χ2 test. RESULTS: From June 2013 through July 2019, 105 participants were randomized (35 per group) and data from 100 participants were analyzed: oxytocin (n=35), oxytocin plus ergonovine (n=33), and oxytocin plus carboprost (n=32). There was no difference in the requirement of additional intraoperative uterotonics across groups (oxytocin [37%] vs oxytocin plus ergonovine [33%] vs oxytocin plus carboprost [34%], P=.932). Uterine tone and calculated blood loss were similar across groups. Incidence of nausea or vomiting was higher in oxytocin plus ergonovine (85%; odds ratio [OR] 5.3, 95% CI 1.7-16.9, P=.003) and oxytocin plus carboprost (72%; OR 2.4, 95% CI 0.9-6.7, P=.086) compared with the oxytocin (51%) group. CONCLUSION: Compared with oxytocin alone, prophylactic use of a combination of uterotonic drugs did not reduce the need for additional uterotonics at cesarean delivery for labor arrest. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01869556.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Balki M, Downey K, Walker A, et al. Prophylactic Administration of Uterotonics to Prevent Postpartum Hemorrhage in Women Undergoing Cesarean Delivery for Arrest of Labor: A Randomized Controlled Trial. Obstet Gynecol. 2021. PMID: 33543897. doi:10.1097/AOG.0000000000004288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。